Newegg Commerce Inc
Change company Symbol lookup
Select an option...
NEGG Newegg Commerce Inc
CHFI China Finance Inc
SU Suncor Energy Inc
CUBI Customers Bancorp Inc
SMIT Schmitt Industries Inc
BA Boeing Co
AMSWA American Software Inc
V Visa Inc
SVFB SVF Investment Corp 2
DMO Western Asset Mortgage Opportunity Fund Inc
Go

Consumer Discretionary : Internet & Direct Marketing Retail | Small Cap Value
Company profile

Newegg Commerce, Inc. is a technology-focused e-commerce company in North America. The Company has developed an online marketplace that delivers value to consumers, brands, and sellers in the technology products sector. It operates business-to-consumer (B2C) platforms, business-to-business (B2B) operations, and other online platforms. Its B2C platform focuses on selling information technology (IT) products, through its platforms, namely Newegg.Com, Newegg.Ca, And Newegg Global. The Company’s B2B platform focuses on providing office and IT equipment, through its neweggbusiness.com platform. Its platforms offer a suite of e-commerce solutions, including product listing, fulfillment, marketing, customer service and other value-added tools and services. The Company’s product categories offered through its platforms, such as computer system, components, electronics, gaming, networking and smart home, office solutions, software and services, automotive and industrial, and health and sports.

Closing Price
$2.02
Day's Change
0.06 (3.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.12
Day's Low
1.94
Volume
(Light)
Volume:
975,007

10-day average volume:
9,450,430
975,007

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

6:25 am ET January 24, 2023 (BusinessWire) Print

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

OVERALL FINANCIAL RESULTS

                  Q4
                                                                        Q4                                                               Full Year
-------------------------------------- ---------------------------------------------------------------                         ---------------------------------------------------------------
 ($ in Millions, except EPS)
                                                 2022                  2021                % Change                   2022                  2021                % Change
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 Reported Sales
                                               $23,706               $24,804                (4.4)%                  $94,943               $93,775                 1.3%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 Net Earnings
                                                $3,520                $4,736               (25.7)%                  $17,941               $20,878               (14.1)%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 EPS (diluted)
                                                $1.33                 $1.77                (24.9)%                   $6.73                 $7.81                (13.8)%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
                                         
                   Q4                                                   Q4                                                               Full Year
-------------------------------------- ---------------------------------------------------------------                         ---------------------------------------------------------------
 Non-GAAP* ($ in Millions, except EPS)
                                                 2022                  2021                % Change                   2022                  2021                % Change
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 Operational Sales(1,2)
                                                       0.9%                           6.1%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 Adjusted Operational Sales(1,3)
                                                       0.8%                           6.2%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------
 Adjusted Net Earnings(1,4)
                                                $6,218                $5,678                 9.5%                   $27,038               $26,195                 3.2%
-------------------------------------- --------------------- --------------------- ---------------------                       --------------------- --------------------- ---------------------

(1) Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules (2) Excludes the impact of translational currency (3) Excludes the net impact of acquisitions and divestitures and translational currency (4)Excludes intangible amortization expense and special items Note: values may have been rounded

REGIONAL SALES RESULTS

 Q4                                      % Change                                                          % Change
                      ------------------------------------------------------------------------------------------------------------------------------------
 ($ in Millions)
                                2022                  2021                Reported          Operational(1,2)          Currency              Adjusted
                                                                                                                                        Operational(1,3)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 U.S.
                              $12,516               $12,163                 2.9%                  2.9                    -                    2.7
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 International
                               11,190                12,641                (11.5)                (1.1)                 (10.4)                (1.0)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Worldwide
                              $23,706               $24,804                (4.4)%                 0.9                  (5.3)                  0.8
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
                                                                                                                   
              
                                                                                                                   
              
                                                                                                                   
              
 Full Year                               % Change                                                          % Change
                      ------------------------------------------------------------------------------------------------------------------------------------
 ($ in Millions)
                                2022                  2021                Reported          Operational(1,2)          Currency              Adjusted
                                                                                                                                        Operational(1,3)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 U.S.
                              $48,580               $47,156                 3.0%                  3.0                    -                    3.0
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 International
                               46,363                46,619                (0.6)%                 9.1                  (9.7)                  9.3
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------

1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been rounded

SEGMENT SALES RESULTS

 Q4
                                                                                        % Change
                                                                  ------------------------------------------------------------------------------------
 ($ in Millions)
                                2022                  2021                Reported          Operational(1,2)          Currency              Adjusted
                                                                                                                                        Operational(1,3)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Consumer Health(4)
                              $ 3,767               $ 3,728                 1.0%                  6.4                  (5.4)                  6.4
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Pharmaceutical(4)
                               13,163                14,217                (7.4)                 (2.5)                 (4.9)                 (2.3)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 MedTech
                               6,776                 6,859                 (1.2)                  4.9                  (6.1)                  4.4
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Worldwide
                              $ 23,706              $ 24,804               (4.4)%                 0.9                  (5.3)                  0.8
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
                     
                     
 Full Year
                                                                                        % Change
                                                                  ------------------------------------------------------------------------------------
 ($ in Millions)
                                2022                  2021                Reported          Operational(1,2)          Currency              Adjusted
                                                                                                                                        Operational(1,3)
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Consumer Health
                              $ 14,953              $ 15,035               (0.5)%                 3.6                  (4.1)                  3.9
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 Pharmaceutical
                               52,563                51,680                 1.7                   6.7                  (5.0)                  6.8
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
 MedTech
                               27,427                27,060                 1.4                   6.2                  (4.8)                  6.1
--------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------

(1) Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules (2) Excludes the impact of translational currency (3) Excludes the net impact of acquisitions and divestitures and translational currency (4) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes Note: Values may have been rounded

FULL YEAR 2022 SEGMENT COMMENTARY: Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

Consumer Health Consumer Health worldwide adjusted operational sales increased 3.9%* predominately driven by over-the-counter (OTC) products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, as well as upper respiratory products and digestive health products in the international markets. Additionally, Skin Health/Beauty adjusted operational growth was primarily driven by NEUTROGENA outside the U.S. Growth was partially offset by Oral Care in the international markets.

Pharmaceutical Pharmaceutical worldwide adjusted operational sales grew 6.8%*, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by declines in sales of REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, and ZYTIGA (abiratone acetate), an oral, once daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

MedTech MedTech worldwide adjusted operational sales grew 6.1%*, driven primarily by electrophysiology products in Interventional Solutions, contact lenses in Vision, and wound closure products in General Surgery.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER: The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investors section of the company's website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com.

                                                                                               Regulatory                                                                                              DePuy Synthes Receives FDA Clearance for TELIGEN System                                                                                                                                          Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------
                                                                                                                                                                                                       Press Release
                                                                                                                                                                                                      ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                       Press Release
                                                                                                                                                                                                      ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              Data Release                                                                                             New TREMFYA (guselkumab) Data Shows an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis  Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------
 Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio                          Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension  Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life                     Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population              Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying Stroke-Inducing Blood Clots                                                                                         Press Release
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                 Other                                                                                                 Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board                                                                                                                               Press Release
                                                                                                                                                                                                      ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------

FULL-YEAR 2023 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

 ($ in Billions, except EPS)                                           January 2023
-------------------------------------------------------- --------------------------------------
 Adjusted Operational Sales(1,2,5)                           3.5% - 4.5% / 4.0%
 Change vs. Prior Year / Mid-point
-------------------------------------------------------- --------------------------------------
 Operational Sales(2,5)/ Mid-point(2,5)                   $96.9B - $97.9B / $97.4B
 Change vs. Prior Year / Mid-point                           4.5% - 5.5% / 5.0%
-------------------------------------------------------- --------------------------------------
 Estimated Reported Sales(3,5)/ Mid-point(3,5)            $96.9B - $97.9B / $97.4B
 Change vs. Prior Year / Mid-point                           4.5% - 5.5% / 5.0%
-------------------------------------------------------- --------------------------------------
                                        
-------------------------------------------------------- --------------------------------------
 Adjusted Operational EPS (Diluted)(2,4)/ Mid-point(2,4)  $10.40 - $10.60 / $10.50
 Change vs. Prior Year / Mid-point                           2.5% - 4.5% / 3.5%
-------------------------------------------------------- --------------------------------------

(1)Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures (2) Non-GAAP financial measure; excludes the impact of translational currency (3) Calculated using Euro Average Rate: January 2023 = $1.08 (Illustrative purposes only) (4)Non-GAAP financial measure; excludes intangible amortization expense and special items (5)Excludes COVID-19 Vaccine Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON: At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES: * "Operational sales growth" excluding the impact of translational currency, "adjusted operational sales growth" excluding the net impact of acquisitions and divestitures and translational currency, as well as "adjusted net earnings", "adjusted diluted earnings per share" and "adjusted operational diluted earnings per share" excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at quarterly results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS: This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company's Consumer Health business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company's ability to satisfy the necessary conditions to consummate the separation of the Company's Consumer Health business on a timely basis or at all; the Company's ability to successfully separate the Company's Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company's ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company's ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Supplementary Sales Data
                                                                                                                                    
----------------------------------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
(Unaudited; Dollars in Millions)                                                                                                                             FOURTH QUARTER                                                                                                                                                                                                                         TWELVE MONTHS
----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Percent Change                                                                                                                                           Percent Change
----------------------------------------------- ------------------------------  -------------------- -------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------                             ------------------------------  -------------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------
                      2022                                    2022                        2021                         Total                          Operations                         Currency                            2022                        2021                         Total                    Operations                    Currency
----------------------------------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------                       ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------
Sales to customers by
segment of business
                                                                                                                                    
Consumer Health (1)
   U.S.                                                            $      1,696                1,529                1,529                 10.9       10.9   %                          10.9                      -          -                      $                    $      6,599                6,516                6,516                  1.3        1.3   %                                     1.3                    -          -  
   International                                       2,071                2,199                2,199                 (5.8       (5.8 )                                     3.2        3.2                   (9.0       (9.0 )                             8,354                8,519                8,519                 (1.9       (1.9 )                                     5.3                  5.3                 (7.2       (7.2 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                    3,767                3,728                3,728                  1.0        1.0                    6.4        6.4                   (5.4       (5.4 )                            14,953               15,035               15,035                 (0.5       (0.5 )                                     3.6                  3.6                 (4.1       (4.1 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
Pharmaceutical (1)
   U.S.                                                7,375                7,418                7,418                 (0.6       (0.6 )                                    (0.6       (0.6 )                                       -          -           28,604               27,954               27,954                  2.3        2.3                    2.3                  2.3                    -          -  
   International                                       5,788                6,799                6,799                (14.9      (14.9 )                                    (4.5       (4.5 )                                   (10.4      (10.4                    )         23,959               23,726               23,726                  1.0        1.0                   11.9                 11.9                (10.9      (10.9 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                   13,163               14,217               14,217                 (7.4       (7.4 )                                    (2.5       (2.5 )                                    (4.9       (4.9 )                            52,563               51,680               51,680                  1.7        1.7                    6.7                  6.7                 (5.0       (5.0 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
Pharmaceutical excluding COVID-19 Vaccine (1,3)
   U.S.                                                7,375                7,205                7,205                  2.4        2.4                    2.4        2.4                      -          -           28,484               27,320               27,320                  4.3        4.3                    4.3                  4.3                    -          -  
   International                                       5,099                5,394                5,394                 (5.5       (5.5 )                                     6.0        6.0                  (11.5      (11.5                    )         21,900               21,975               21,975                 (0.3       (0.3 )                                    10.3                 10.3                (10.6      (10.6 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                   12,474               12,599               12,599                 (1.0       (1.0 )                                     3.9        3.9                   (4.9       (4.9 )                            50,384               49,295               49,295                  2.2        2.2                    6.9                  6.9                 (4.7       (4.7 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
MedTech (2)
   U.S.                                                3,445                3,216                3,216                  7.1        7.1                    7.1        7.1                      -          -           13,377               12,686               12,686                  5.4        5.4                    5.4                  5.4                    -          -  
   International                                       3,331                3,643                3,643                 (8.6       (8.6 )                                     2.9        2.9                  (11.5      (11.5 )                            14,050               14,374               14,374                 (2.3       (2.3 )                                     6.9                  6.9                 (9.2       (9.2 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                    6,776                6,859                6,859                 (1.2       (1.2 )                                     4.9        4.9                   (6.1       (6.1 )                            27,427               27,060               27,060                  1.4        1.4                    6.2                  6.2                 (4.8       (4.8 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
U.S.                                                  12,516               12,163               12,163                  2.9        2.9                    2.9        2.9                      -          -           48,580               47,156               47,156                  3.0        3.0                    3.0                  3.0                    -          -  
International                                         11,190               12,641               12,641                (11.5      (11.5 )                                    (1.1       (1.1 )                                   (10.4      (10.4 )                            46,363               46,619               46,619                 (0.6       (0.6 )                                     9.1                  9.1                 (9.7       (9.7 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
Worldwide                                             23,706               24,804               24,804                 (4.4       (4.4 )                                     0.9        0.9                   (5.3       (5.3 )                            94,943               93,775               93,775                  1.3        1.3                    6.1                  6.1                 (4.8       (4.8 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
U.S.                                                  12,516               11,950               11,950                  4.7        4.7                    4.7        4.7                      -          -           48,460               46,522               46,522                  4.2        4.2                    4.2                  4.2                    -          -  
International                                         10,501               11,236               11,236                 (6.5       (6.5 )                                     4.4        4.4                  (10.9      (10.9 )                            44,304               44,868               44,868                 (1.3       (1.3 )                                     8.2                  8.2                 (9.5       (9.5 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
Worldwide excluding COVID-19 Vaccine (3)                           $     23,017               23,186               23,186                 (0.7       (0.7 )                    %                           4.6                   (5.3       (5.3 )                                       $                    $     92,764               91,390               91,390                  1.5        1.5   %                                     6.2                 (4.7       (4.7 )
----------------------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                                    
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
                                                                                                                                    
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
Johnson & Johnson and Subsidiaries
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Supplementary Sales Data
                                                                                                                      
--------------------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
(Unaudited; Dollars in Millions)                                                                                                               FOURTH QUARTER                                                                                                                                                                                                                         TWELVE MONTHS
--------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                Percent Change                                                                                                                                           Percent Change
--------------------------------- ------------------------------  -------------------- -------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------                             ------------------------------  -------------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------
               2022                             2022                        2021                         Total                          Operations                         Currency                            2022                        2021                         Total                    Operations                    Currency
--------------------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------                       ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------
Sales to customers by
geographic area
                                                                                                                      
U.S.                                                 $     12,516               12,163               12,163                  2.9        2.9   %                           2.9                      -          -                      $                    $     48,580               47,156               47,156                  3.0        3.0   %                                     3.0                    -          -  
--------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                      
Europe                                   5,816                6,925                6,925                (16.0      (16.0                    )                 (6.3       (6.3 )                                    (9.7       (9.7 )                            23,449               23,594               23,594                 (0.6       (0.6 )                                    11.0                 11.0                (11.6      (11.6 )
Western Hemisphere excluding U.S.        1,545                1,459                1,459                  5.9        5.9                   11.8       11.8                   (5.9       (5.9 )                             6,125                5,750                5,750                  6.5        6.5                   10.2                 10.2                 (3.7       (3.7 )
Asia-Pacific, Africa                     3,829                4,257                4,257                (10.0      (10.0 )                                     3.1        3.1                  (13.1      (13.1 )                            16,789               17,275               17,275                 (2.8       (2.8 )                                     6.2                  6.2                 (9.0       (9.0 )
--------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
International                           11,190               12,641               12,641                (11.5      (11.5 )                                    (1.1       (1.1 )                                   (10.4      (10.4 )                            46,363               46,619               46,619                 (0.6       (0.6 )                                     9.1                  9.1                 (9.7       (9.7 )
--------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                      
Worldwide                                            $     23,706               24,804               24,804                 (4.4       (4.4 )                    %                           0.9                   (5.3       (5.3 )                                       $                    $     94,943               93,775               93,775                  1.3        1.3   %                                     6.1                 (4.8       (4.8 )
--------------------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                      
Johnson & Johnson and Subsidiaries
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Condensed Consolidated Statement of Earnings
                                                                                                                   
----------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
(Unaudited; in Millions Except Per Share Figures)                                                                                                                                       FOURTH QUARTER
----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                   
                               2022                                                                                2022                                                                                       2021                                                  Percent
----------------------------------------------------------------- -------------------------------------------------------------------------------------------------                           ----------------------------------------------------------------------
                                                                                             Percent                                    Percent                     Increase
                              Amount                                                    Amount                                    to Sales                           Amount                     to Sales                    (Decrease)
----------------------------------------------------------------- -----------------------------------------------   -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------
Sales to customers                                                                   $  23,706                  100.0      100.0                      $                    $     24,804                100.0                100.0                 (4.4       (4.4                    )
Cost of products sold                                                 7,765                   32.8       32.8            7,955                 32.1                 32.1                 (2.4       (2.4                    )
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Gross Profit                                                         15,941                   67.2       67.2           16,849                 67.9                 67.9                 (5.4       (5.4                    )
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Selling, marketing and administrative expenses                        6,512                   27.4       27.4            7,154                 28.9                 28.9                 (9.0       (9.0                    )
Research and development expense                                      3,841                   16.2       16.2            4,720                 19.0                 19.0                (18.6      (18.6                    )
In-process research and development                                     173                    0.7        0.7                0                  0.0                  0.0
Interest (income) expense, net                                          (77 )                                    (0.3       (0.3 )                                47                  0.2                  0.2
Other (income) expense, net                                           1,207                    5.1        5.1                9                  0.0                  0.0
Restructuring                                                            84                    0.4        0.4               83                  0.3                  0.3
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- --------------------
Earnings before provision for taxes on income                         4,201                   17.7       17.7            4,836                 19.5                 19.5                (13.1      (13.1                    )
Provision for taxes on income                                           681                    2.9        2.9              100                  0.4                  0.4                581.0      581.0  
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Net earnings                                                                         $   3,520                   14.8       14.8                      $                    $      4,736                 19.1                 19.1                (25.7      (25.7                    )
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                   
Net earnings per share (Diluted)                                                     $    1.33                      $                               $                    $                    $       1.77                (24.9                (24.9                (24.9      (24.9                    )
                                                                                                                   
Average shares outstanding (Diluted)                                2,650.1                         2,670.2
                                                                                                                   
Effective tax rate                                                     16.2   %                                            2.1 %
                                                                                                                   
----------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
Adjusted earnings before provision for taxes and net earnings (1)
   Earnings before provision for taxes on income                                     $   7,418                   31.3       31.3                      $                    $      6,339                 25.6                 25.6                 17.0       17.0  
   Net earnings                                                                      $   6,218                   26.2       26.2                      $                    $      5,678                 22.9                 22.9                  9.5        9.5  
   Net earnings per share (Diluted)                                                  $    2.35                      $                               $                    $                    $       2.13                 10.3                 10.3                 10.3       10.3  
   Effective tax rate                                                  16.2   %                                           10.4 %
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ------------------------------  -------------------- -------------------- ---------- --------------------
                                                                                                                   
Johnson & Johnson and Subsidiaries
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Condensed Consolidated Statement of Earnings
                                                                                                                   
----------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
(Unaudited; in Millions Except Per Share Figures)                                                                                                                                        TWELVE MONTHS
----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                         
                               2022                                                                                2022                                                                                       2021                                                  Percent
----------------------------------------------------------------- -------------------------------------------------------------------------------------------------                           ----------------------------------------------------------------------
                                                                                             Percent                                    Percent                     Increase
                              Amount                                                    Amount                                    to Sales                           Amount                     to Sales                    (Decrease)
----------------------------------------------------------------- -----------------------------------------------   -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------
Sales to customers                                                                   $  94,943                  100.0      100.0                      $                    $     93,775                100.0                100.0                  1.3        1.3  
Cost of products sold                                                31,089                   32.7       32.7           29,855                 31.8                 31.8                  4.1        4.1  
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Gross Profit                                                         63,854                   67.3       67.3           63,920                 68.2                 68.2                 (0.1       (0.1                    )
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Selling, marketing and administrative expenses                       24,765                   26.1       26.1           24,659                 26.3                 26.3                  0.4        0.4  
Research and development expense                                     14,603                   15.4       15.4           14,714                 15.7                 15.7                 (0.8       (0.8                    )
In-process research and development                                     783                    0.8        0.8              900                  1.0                  1.0
Interest (income) expense, net                                         (214 )                                    (0.2       (0.2 )                               130                  0.1                  0.1
Other (income) expense, net                                           1,871                    2.0        2.0              489                  0.5                  0.5
Restructuring                                                           321                    0.3        0.3              252                  0.3                  0.3
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- --------------------
Earnings before provision for taxes on income                        21,725                   22.9       22.9           22,776                 24.3                 24.3                 (4.6       (4.6                    )
Provision for taxes on income                                         3,784                    4.0        4.0            1,898                  2.0                  2.0                 99.4       99.4  
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
Net earnings                                                                         $  17,941                   18.9       18.9                      $                    $     20,878                 22.3                 22.3                (14.1      (14.1                    )
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- --------------------
                                                                                                                   
Net earnings per share (Diluted)                                                     $    6.73                      $                               $                    $                    $       7.81                (13.8                (13.8                (13.8      (13.8                    )
                                                                                                                   
Average shares outstanding (Diluted)                                2,663.9                         2,674.0
                                                                                                                   
Effective tax rate                                                     17.4   %                                            8.3 %
                                                                                                                   
----------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- --------------------------------
Adjusted earnings before provision for taxes and net earnings (1)
   Earnings before provision for taxes on income                                     $  31,880                   33.6       33.6                      $                    $     30,464                 32.5                 32.5                  4.6        4.6  
   Net earnings                                                                      $  27,038                   28.5       28.5                      $                    $     26,195                 27.9                 27.9                  3.2        3.2  
   Net earnings per share (Diluted)                                                  $   10.15                      $                               $                    $                    $       9.80                  3.6                  3.6                  3.6        3.6  
   Effective tax rate                                                  15.2   %                                           14.0 %
----------------------------------------------------------------- -------------------- ------- -------------------- -------------------- ------------------------------  -------------------- -------------------- ---------- --------------------
                                                                                                                   
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                             Fourth Quarter                                                          Fourth Quarter                                                                                                                                                                                      Fourth Quarter                                                                                                                                                                                                                                                                                                                                                             Twelve Months Ended
----------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------     --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(Dollars in Millions Except Per Share Data)                             (Dollars in Millions Except Per Share Data)                                                                                           2022                                                                                                                                                                         2021                                                                                                                                                                         2022                                                                                                                                                                         2021
----------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
Net Earnings, after tax- as reported                                    Net Earnings, after tax- as reported                                                                                             $3,520                                                                                                       $4,736                                                          $4,736                                                                                                      $17,941                                                         $17,941                                                                                                      $20,878                                                         $20,878                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Pre-tax Adjustments                                                     Pre-tax Adjustments
Intangible Asset Amortization expense                                   Intangible Asset Amortization expense                                                                                             1,061                                                                                                        1,121                                                           1,121                                                                                                        4,305                                                           4,305                                                                                                        4,697                                                           4,697                                             
                                                     Litigation related Litigation related                                                                                                                  262                                                                                                          274                                                             274                                                                                                          866                                                             866                                                                                                        2,328                                                           2,328                                             
IPR&D                                                                   IPR&D                                                                                                                               173                                                                                                            -                                                               -                                                                                                          783                                                             783                                                                                                          900                                                             900  
Restructuring related                                                   Restructuring related                                                                                                               140                                                                                                          140                                                             140                                                                                                          463                                                             463                                                                                                          473                                                             473                                             
Acquisition, integration and divestiture related (1) Acquisition, integration and divestiture related (1)                                                             196                                                                                                           26                                                              26                                                                                                          196                                                             196                                                                                                         (478                                                            (478                                                               )
(Gains)/losses on securities                                            (Gains)/losses on securities                                                                                                          6                                                                                                         (198                                                            (198                                                               )                                                             690                                                             690                                                                                                         (533                                                            (533                                                               )
Medical Device Regulation (2)                                           Medical Device Regulation (2)                                                                                                        88                                                                                                           73                                                              73                                                                                                          296                                                             296                                                                                                          234                                                             234  
COVID-19 Vaccine related costs (3)                                      COVID-19 Vaccine related costs (3)                                                                                                  821                                                                                                            -                                                               -                                                                                                        1,474                                                           1,474                                                                                                            -                                                               -  
Consumer Health separation costs                                        Consumer Health separation costs                                                                                                    470                                                                                                           67                                                              67                                                                                                        1,089                                                           1,089                                                                                                           67                                                              67  
Other                                                                   Other                                                                                                                                 -                                                                                                            -                                                               -                                                                                                           (7                                                              (7 )                                                                                                                             -                                                               -  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Tax Adjustments                                                         Tax Adjustments
Tax impact on special item adjustments (4)                              Tax impact on special item adjustments (4)                                                                                         (507                                                               )                                                            (184                                                            (184                                                               )                                                          (1,592                                                          (1,592                                                               )                                                          (1,281                                                          (1,281                                                               )
Consumer Health separation tax related costs                            Consumer Health separation tax related costs                                                                                         35                                                                                                            -                                                               -                                                                                                          494                                                             494                                                                                                            -                                                               -  
Tax legislation and other tax related                                   Tax legislation and other tax related                                                                                               (47                                                               )                                                            (377                                                            (377 )                                                                                                                            40                                                              40                                                                                                       (1,090                                                          (1,090 )
                                                                                                                                                --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
Adjusted Net Earnings, after tax                                        Adjusted Net Earnings, after tax                                                                                                 $6,218                                                                                                       $5,678                                                          $5,678                                                                                                      $27,038                                                         $27,038                                                                                                      $26,195                                                         $26,195                                             
Average shares outstanding (Diluted)                                    Average shares outstanding (Diluted)                                                                                            2,650.1                                                                                                      2,670.2                                                         2,670.2                                                                                                      2,663.9                                                         2,663.9                                                                                                      2,674.0                                                         2,674.0                                             
Adjusted net earnings per share (Diluted)                               Adjusted net earnings per share (Diluted)                                                                                         $2.35                                                                                                        $2.13                                                           $2.13                                                                                                       $10.15                                                          $10.15                                                                                                        $9.80                                                           $9.80                                             
Operational adjusted net earnings per share (Diluted)                   Operational adjusted net earnings per share (Diluted)                                                                             $2.46                                                                                                       $10.70                                                                                                                          $10.70                                                          $10.70                                                          $10.70                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Notes:                                                                  Notes:
                                                                    (1) Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition. Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                    (2) European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                    (3) COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual requirements.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
                                                                                
                                                                                                              Adjusted Operational Sales Growth
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                         FOURTH QUARTER 2022 ACTUAL vs. 2021 ACTUAL
                                                                                                                          Segments
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           
             Consumer Health               Consumer Health            Consumer Health           Pharmaceutical             Pharmaceutical                MedTech                    MedTech                    Total                      Total
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW As Reported                                           1.0        1.0           %                          (7.4       (7.4          )%                          (1.2       (1.2          )%                          (4.4       (4.4          )%
--------------------------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
U.S.                                                    10.9       10.9           %                          (0.6       (0.6          )%                           7.1        7.1           %                           2.9        2.9           %
International                                           (5.8       (5.8          )%                         (14.9      (14.9          )%                          (8.6       (8.6          )%                         (11.5      (11.5          )%
                                                                           
WW Currency                                             (5.4       (5.4           )                          (4.9       (4.9           )                          (6.1       (6.1           )                          (5.3       (5.3           )
U.S.                                                       -          -                      -          -                      -          -                      -          -  
International                                           (9.0       (9.0           )                         (10.4      (10.4           )                         (11.5      (11.5           )                         (10.4      (10.4           )
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW Operational                                           6.4        6.4           %                          (2.5       (2.5          )%                           4.9        4.9           %                           0.9        0.9           %
--------------------------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
U.S.                                                    10.9       10.9           %                          (0.6       (0.6          )%                           7.1        7.1           %                           2.9        2.9           %
International                                            3.2        3.2           %                          (4.5       (4.5          )%                           2.9        2.9           %                          (1.1       (1.1          )%
                                                                           
Interventional Solutions
Abiomed                                                 (0.5                            (0.5                 (0.5                            (0.5                 (0.5       (0.5           )                          (0.1       (0.1           )
   U.S.                                                 (1.0                            (1.0                 (1.0                            (1.0                 (1.0       (1.0           )                          (0.3       (0.3           )
   International                                         0.0                             0.0                  0.0                             0.0                  0.0        0.0                    0.0        0.0  
                                                                           
All Other Acquisitions and Divestitures                  0.0        0.0                    0.2        0.2                    0.0        0.0                    0.1        0.1  
   U.S.                                                  0.1        0.1                    0.2        0.2                   (0.2       (0.2           )                           0.1        0.1  
   International                                         0.0        0.0                    0.1        0.1                    0.1        0.1                    0.1        0.1  
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW Adjusted Operational                                  6.4        6.4           %                          (2.3       (2.3          )%                           4.4        4.4           %                           0.8        0.8           %
======================================= ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
U.S.                                                    11.0       11.0           %                          (0.4       (0.4          )%                           5.9        5.9           %                           2.7        2.7           %
International                                            3.2        3.2           %                          (4.4       (4.4          )%                           3.0        3.0           %                          (1.0       (1.0          )%
                                                                           
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
                                                                                
                                                                                                              Adjusted Operational Sales Growth
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                          TWELVE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
                                                                                                                          Segments
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           
             Consumer Health               Consumer Health            Consumer Health           Pharmaceutical             Pharmaceutical                MedTech                    MedTech                    Total                      Total
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW As Reported                                          (0.5       (0.5          )%                           1.7        1.7           %                           1.4        1.4           %                           1.3        1.3           %
--------------------------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
U.S.                                                     1.3        1.3           %                           2.3        2.3           %                           5.4        5.4           %                           3.0        3.0           %
International                                           (1.9       (1.9          )%                           1.0        1.0           %                          (2.3       (2.3          )%                          (0.6       (0.6          )%
                                                                           
WW Currency                                             (4.1       (4.1           )                          (5.0       (5.0           )                          (4.8       (4.8           )                          (4.8       (4.8           )
U.S.                                                       -          -                      -          -                      -          -                      -          -  
International                                           (7.2       (7.2           )                         (10.9      (10.9           )                          (9.2       (9.2           )                          (9.7       (9.7           )
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW Operational                                           3.6        3.6           %                           6.7        6.7           %                           6.2        6.2           %                           6.1        6.1           %
--------------------------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
U.S.                                                     1.3        1.3           %                           2.3        2.3           %                           5.4        5.4           %                           3.0        3.0           %
International                                            5.3        5.3           %                          11.9       11.9           %                           6.9        6.9           %                           9.1        9.1           %
                                                                           
All Other Acquisitions and Divestitures                  0.3        0.3                    0.1        0.1                   (0.1       (0.1           )                           0.1        0.1  
   U.S.                                                  0.2        0.2                    0.2        0.2                   (0.4       (0.4           )                           0.0        0.0  
   International                                         0.5        0.5                    0.1        0.1                    0.1        0.1                    0.2        0.2  
                                                                           
--------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
WW Adjusted Operational                                  3.9        3.9           %                           6.8        6.8           %                           6.1        6.1           %                           6.2        6.2           %
======================================= ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
U.S.                                                     1.5        1.5           %                           2.5        2.5           %                           5.0        5.0           %                           3.0        3.0           %
International                                            5.8        5.8           %                          12.0       12.0           %                           7.0        7.0           %                           9.3        9.3           %
                                                                           
 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                 REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------           ------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
            FOURTH QUARTER                                                                                                                        FOURTH QUARTER                                                                                                                                                                                                                                                 TWELVE MONTHS
------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                                 ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        % Change                                                                                                                                                               % Change
                                                                                                                                               ------------------------------------------------------------------------------------------------------------------------                                                                                                                                                                      --------------------------------------------------------------------------------------------------------------
                                        2022                             2021                          Reported                               Operational (1)                              Currency                                                                          2022                             2021                          Reported                               Operational (1)                         Currency
                                                           ----------------------------------------                       -------------------- ----------------------------------------  ----------------------------------------  ----------------------------------------                                                                              ----------------------------------------                       -------------------- ----------------------------------------  ----------------------------------------  ------------------------------
CONSUMER HEALTH SEGMENT (2,3)
-------------------------------------
OTC
-------------------------------------
US                                                       $                    $                  754                  633                  633                 18.9                    %                 18.9                    %                    -                                       $                                     $                    $                2,782                2,594                2,594                  7.3                    %                  7.3                    %          -  
Intl                                                       815                  811                  811                  0.6                    %                  9.6                    %                 -9.0                    %                                                        3,249                3,034                3,034                  7.1                    %                 14.5                    %       -7.4                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       1,569                1,444                1,444                  8.6                    %                 13.7                    %                 -5.1                    %                                                        6,031                5,627                5,627                  7.2                    %                 11.2                    %       -4.0                    %
SKIN HEALTH / BEAUTY
-------------------------------------
US                                                         573                  538                  538                  6.5                    %                  6.5                    %                    -                                                          2,337                2,400                2,400                 -2.6                    %                 -2.6                    %          -  
Intl                                                       515                  546                  546                 -5.6                    %                  4.4                    %                -10.0                    %                                                        2,015                2,141                2,141                 -5.9                    %                  2.2                    %       -8.1                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       1,088                1,084                1,084                  0.4                    %                  5.4                    %                 -5.0                    %                                                        4,352                4,541                4,541                 -4.2                    %                 -0.4                    %       -3.8                    %
ORAL CARE
-------------------------------------
US                                                         164                  159                  159                  3.3                    %                  3.3                    %                    -                                                            635                  637                  637                 -0.3                    %                 -0.3                    %          -  
Intl                                                       207                  246                  246                -16.0                    %                 -8.1                    %                 -7.9                    %                                                          871                1,008                1,008                -13.6                    %                 -7.4                    %       -6.2                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                         370                  405                  405                 -8.4                    %                 -3.7                    %                 -4.7                    %                                                        1,505                1,645                1,645                 -8.5                    %                 -4.7                    %       -3.8                    %
BABY CARE
-------------------------------------
US                                                          93                   90                   90                  3.4                    %                  3.4                    %                    -                                                            357                  378                  378                 -5.5                    %                 -5.5                    %          -  
Intl                                                       264                  309                  309                -14.6                    %                 -7.4                    %                 -7.2                    %                                                        1,104                1,188                1,188                 -7.1                    %                 -1.4                    %       -5.7                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                         356                  399                  399                -10.6                    %                 -5.0                    %                 -5.6                    %                                                        1,461                1,566                1,566                 -6.7                    %                 -2.4                    %       -4.3                    %
WOMEN'S HEALTH
-------------------------------------
US                                                           4                    4                    4                 15.6                    %                 15.6                    %                    -                                                             13                   13                   13                  1.7                    %                  1.7                    %          -  
Intl                                                       217                  230                  230                 -5.7                    %                  4.4                    %                -10.1                    %                                                          891                  905                  905                 -1.5                    %                  7.1                    %       -8.6                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                         220                  233                  233                 -5.5                    %                  4.6                    %                -10.1                    %                                                          904                  917                  917                 -1.5                    %                  7.0                    %       -8.5                    %
WOUND CARE / OTHER
-------------------------------------
US                                                         109                  106                  106                  3.3                    %                  3.3                    %                    -                                                            475                  495                  495                 -4.0                    %                 -4.0                    %          -  
Intl                                                        54                   57                   57                 -7.5                    %                  2.9                    %                -10.4                    %                                                          224                  243                  243                 -8.0                    %                 -3.4                    %       -4.6                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                         163                  164                  164                 -0.5                    %                  3.1                    %                 -3.6                    %                                                          700                  739                  739                 -5.3                    %                 -3.8                    %       -1.5                    %
                                                                                                           
TOTAL CONSUMER HEALTH
-------------------------------------
US                                                       1,696                1,529                1,529                 10.9                    %                 10.9                    %                    -                                                          6,599                6,516                6,516                  1.3                    %                  1.3                    %          -  
Intl                                                     2,071                2,199                2,199                 -5.8                    %                  3.2                    %                 -9.0                    %                                                        8,354                8,519                8,519                 -1.9                    %                  5.3                    %       -7.2                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       $                    $                3,767                3,728                3,728                  1.0                    %                  6.4                    %                 -5.4                    %                                     $                                     $                    $               14,953               15,035               15,035                 -0.5                    %                  3.6                    %       -4.1                    %
                                      ==================== ==================== ==================== ==================== ====================                                                                                                                               ===================================== ===================================== ==================== ==================== ==================== ====================
                                                                                                      
------------------------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- ------------------------------------- ------------------------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------------------
                                                                                                      
    REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                     REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                                                                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)
-------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                -------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
               FOURTH QUARTER                                                                                                                            FOURTH QUARTER                                                                                                                                                                                                         TWELVE MONTHS
-------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                -------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                               % Change                                                                                                                       % Change
                                                                                                                                                      ------------------------------------------------------------------------------------------------------------------------                                                                                                                                    ---------------------------------------------------------------------------------------------------
PHARMACEUTICAL SEGMENT (2,3)                                      2022                           2021                 2021                          Reported                               Operational (1)                              Currency                                        2022                           2021                 2021                          Reported                               Operational (1)                   Currency
--------------------------------------------                      ----------------------------------------  -------------------- -------------------- ----------------------------------------  ----------------------------------------  ----------------------------------------                                            ----------------------------------------  -------------------- -------------------- ----------------------------------------  ----------------------------------------  -------------------
                                                                     
IMMUNOLOGY
--------------------------------------------
US                                                              $                    $                2,805                2,912                2,912                 -3.6                    %                 -3.6                    %                    -                      $                    $                    $               11,036               10,843               10,843                  1.8                    %                  1.8                    %          -
Intl                                                            1,312                1,443                1,443                 -9.1                    %                  2.1                    %                -11.2                    %                      5,899                5,907                5,907                 -0.1                    %                 10.3                    %      -10.4 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                              4,118                4,355                4,355                 -5.4                    %                 -1.8                    %                 -3.6                    %                     16,935               16,750               16,750                  1.1                    %                  4.8                    %       -3.7 %
   REMICADE                                                                             
--------------------------------------------
   US                                                             318                  511                  511                -37.7                    %                -37.7                    %                    -                        1,417                2,019                2,019                -29.8                    %                -29.8                    %          -
   US Exports (4)                                                  41                   39                   39                  5.1                    %                  5.1                    %                    -                          204                  236                  236                -13.6                    %                -13.6                    %          -
   Intl                                                           116                  214                  214                -45.9                    %                -41.3                    %                 -4.6                    %                        722                  935                  935                -22.8                    %                -18.7                    %       -4.1 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             475                  764                  764                -37.8                    %                -36.5                    %                 -1.3                    %                      2,343                3,190                3,190                -26.6                    %                -25.3                    %       -1.3 %
   SIMPONI / SIMPONI ARIA                                                               
--------------------------------------------
   US                                                             280                  287                  287                 -2.2                    %                 -2.2                    %                    -                        1,166                1,127                1,127                  3.5                    %                  3.5                    %          -
   Intl                                                           220                  271                  271                -18.6                    %                 -7.4                    %                -11.2                    %                      1,017                1,148                1,148                -11.4                    %                 -1.4                    %      -10.0 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             501                  559                  559                -10.2                    %                 -4.7                    %                 -5.5                    %                      2,184                2,276                2,276                 -4.0                    %                  1.0                    %       -5.0 %
   STELARA                                                                              
--------------------------------------------
   US                                                           1,621                1,542                1,542                  5.2                    %                  5.2                    %                    -                        6,388                5,938                5,938                  7.6                    %                  7.6                    %          -
   Intl                                                           764                  792                  792                 -3.5                    %                  8.1                    %                -11.6                    %                      3,335                3,196                3,196                  4.4                    %                 15.7                    %      -11.3 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                           2,386                2,334                2,334                  2.3                    %                  6.2                    %                 -3.9                    %                      9,723                9,134                9,134                  6.5                    %                 10.4                    %       -3.9 %
   TREMFYA                                                                              
--------------------------------------------
   US                                                             541                  528                  528                  2.5                    %                  2.5                    %                    -                        1,844                1,503                1,503                 22.7                    %                 22.7                    %          -
   Intl                                                           211                  165                  165                 27.5                    %                 44.5                    %                -17.0                    %                        824                  624                  624                 32.0                    %                 47.8                    %      -15.8 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             752                  693                  693                  8.5                    %                 12.5                    %                 -4.0                    %                      2,668                2,127                2,127                 25.4                    %                 30.1                    %       -4.7 %
   OTHER IMMUNOLOGY                                                                     
--------------------------------------------
   US                                                               3                    6                    6                -53.5                    %                -53.5                    %                    -                           17                   21                   21                -18.4                    %                -18.4                    %          -
   Intl                                                             0                    0                    0 *                    *                    *                    *                    *                                               0                    3                    3 *                    *                    *                    *                    *
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                          -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                               3                    6                    6                -53.3                    %                -53.3                    %                  0.0                    %                         17                   24                   24                -28.2                    %                -28.2                    %        0.0 %
INFECTIOUS DISEASES                                                                     
--------------------------------------------
US                                                                414                  614                  614                -32.6                    %                -32.6                    %                    -                        1,680                2,249                2,249                -25.3                    %                -25.3                    %          -
Intl                                                            1,127                1,818                1,818                -38.0                    %                -31.0                    %                 -7.0                    %                      3,769                3,576                3,576                  5.4                    %                 17.3                    %      -11.9 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                              1,540                2,431                2,431                -36.6                    %                -31.4                    %                 -5.2                    %                      5,449                5,825                5,825                 -6.5                    %                  0.8                    %       -7.3 %
   COVID-19 VACCINE                                                                     
--------------------------------------------
   US                                                               0                  213                  213 *                    *                    *                                       -                    -                          120                  634                  634                -81.1                    %                -81.1                    %          -
   Intl                                                           689                1,405                1,405                -50.9                    %                -45.0                    %                 -5.9                    %                      2,059                1,751                1,751                 17.6                    %                 32.1                    %      -14.5 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             689                1,619                1,619                -57.4                    %                -52.2                    %                 -5.2                    %                      2,179                2,385                2,385                 -8.6                    %                  2.0                    %      -10.6 %
   EDURANT / rilpivirine                                                                
--------------------------------------------
   US                                                               9                   10                   10                  1.2                    %                  1.2                    %                    -                           36                   41                   41                -10.8                    %                -10.8                    %          -
   Intl                                                           281                  220                  220                 27.6                    %                 39.2                    %                -11.6                    %                        972                  953                  953                  2.0                    %                 12.7                    %      -10.7 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             290                  230                  230                 26.5                    %                 37.6                    %                -11.1                    %                      1,008                  994                  994                  1.5                    %                 11.8                    %      -10.3 %
   PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA                                            
--------------------------------------------
   US                                                             398                  380                  380                  4.7                    %                  4.7                    %                    -                        1,494                1,508                1,508                 -1.0                    %                 -1.0                    %          -
   Intl                                                            95                  135                  135                -29.5                    %                -20.5                    %                 -9.0                    %                        449                  575                  575                -21.9                    %                -13.4                    %       -8.5 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                             493                  515                  515                 -4.3                    %                 -1.9                    %                 -2.4                    %                      1,943                2,083                2,083                 -6.7                    %                 -4.4                    %       -2.3 %
   OTHER INFECTIOUS DISEASES                                                            
--------------------------------------------
   US                                                               6                   11                   11                -47.1                    %                -47.1                    %                    -                           30                   66                   66                -55.5                    %                -55.5                    %          -
   Intl                                                            61                   57                   57                  7.3                    %                 18.0                    %                -10.7                    %                        289                  297                  297                 -2.6                    %                  3.6                    %       -6.2 %
                                             -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                              67                   68                   68                 -1.6                    %                  7.4                    %                 -9.0                    %                        318                  363                  363                -12.3                    %                 -7.2                    %       -5.1 %
 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                   REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                       REPORTED SALES vs. PRIOR PERIOD ($MM)
                                                                        FOURTH QUARTER                                                                                                            TWELVE MONTHS
------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------                              -------------------- ------------------------------------------------------------------------------------------------------------
                                                  % Change                                                        % Change
                                                                                                                          ------------------------------------------------                                                                                                               ------------------------------------------------
                             2022                 2021                 2021          Reported   Operational (1)         Currency                      2022                 2021                 2021          Reported   Operational (1)         Currency
                                                           -------------------- -------------------- -------------------- ---------  --------------  -------------------------                                            -------------------- -------------------- -------------------- ---------  --------------  -------------------------
NEUROSCIENCE
-------------------------------------
US                                                     912                  912                  899                  899   1.4    %     1.4       %     -                  3,570                3,570                3,570                3,347                3,347   6.7    %     6.7       %     -  
Intl                                                   825                  825                  890                  890  -7.2    %     3.3       % -10.5                    %                3,323                3,323                3,323                3,641                3,641  -8.7    %     0.4       %  -9.1                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                   1,737                1,737                1,789                1,789  -2.8    %     2.4       %  -5.2                    %                6,893                6,893                6,893                6,988                6,988  -1.4    %     3.4       %  -4.8                    %
   CONCERTA / Methylphenidate
-------------------------------------
   US                                                   37                   37                   55                   55 -34.3    %   -34.3       %     -                    151                  151                  151                  172                  172 -12.5    %   -12.5       %     -  
   Intl                                                131                  131                  123                  123   6.5    %    20.3       % -13.8                    %                  493                  493                  493                  495                  495  -0.4    %     9.9       % -10.3                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  168                  168                  178                  178  -6.2    %     3.4       %  -9.6                    %                  644                  644                  644                  667                  667  -3.5    %     4.1       %  -7.6                    %
   INVEGA SUSTENNA / XEPLION /
   INVEGA TRINZA / TREVICTA
-------------------------------------
   US                                                  678                  678                  668                  668   1.8    %     1.8       %     -                  2,714                2,714                2,714                2,550                2,550   6.5    %     6.5       %     -  
   Intl                                                329                  329                  361                  361  -8.8    %     2.7       % -11.5                    %                1,426                1,426                1,426                1,472                1,472  -3.1    %     7.8       % -10.9                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                1,008                1,008                1,029                1,029  -2.0    %     2.1       %  -4.1                    %                4,140                4,140                4,140                4,022                4,022   3.0    %     6.9       %  -3.9                    %
   RISPERDAL CONSTA
-------------------------------------
   US                                                   62                   62                   77                   77 -19.4    %   -19.4       %     -                    257                  257                  257                  287                  287 -10.4    %   -10.4       %     -  
   Intl                                                 50                   50                   63                   63 -21.5    %    -9.7       % -11.8                    %                  228                  228                  228                  305                  305 -25.3    %   -15.5       %  -9.8                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  112                  112                  140                  140 -20.4    %   -15.0       %  -5.4                    %                  485                  485                  485                  592                  592 -18.1    %   -13.0       %  -5.1                    %
   OTHER NEUROSCIENCE
-------------------------------------
   US                                                  134                  134                   99                   99  35.5    %    35.5       %     -                    447                  447                  447                  338                  338  32.4    %    32.4       %     -  
   Intl                                                315                  315                  342                  342  -7.7    %     0.3       %  -8.0                    %                1,176                1,176                1,176                1,368                1,368 -14.1    %    -7.5       %  -6.6                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  449                  449                  441                  441   2.0    %     8.2       %  -6.2                    %                1,623                1,623                1,623                1,706                1,706  -4.9    %     0.4       %  -5.3                    %
ONCOLOGY
-------------------------------------
US                                                   1,857                1,857                1,594                1,594  16.5    %    16.5       %     -                  6,930                6,930                6,930                5,958                5,958  16.3    %    16.3       %     -  
Intl                                                 2,069                2,069                2,184                2,184  -5.3    %     6.8       % -12.1                    %                9,052                9,052                9,052                8,590                8,590   5.4    %    17.3       % -11.9                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                   3,927                3,927                3,778                3,778   3.9    %    10.9       %  -7.0                    %               15,983               15,983               15,983               14,548               14,548   9.9    %    16.9       %  -7.0                    %
   DARZALEX
-------------------------------------
   US                                                1,139                1,139                  867                  867  31.4    %    31.4       %     -                  4,210                4,210                4,210                3,169                3,169  32.8    %    32.8       %     -  
   Intl                                                944                  944                  778                  778  21.3    %    36.7       % -15.4                    %                3,767                3,767                3,767                2,854                2,854  32.0    %    47.0       % -15.0                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                2,083                2,083                1,645                1,645  26.6    %    33.9       %  -7.3                    %                7,977                7,977                7,977                6,023                6,023  32.4    %    39.5       %  -7.1                    %
   ERLEADA
-------------------------------------
   US                                                  275                  275                  235                  235  17.2    %    17.2       %     -                    968                  968                  968                  813                  813  19.2    %    19.2       %     -  
   Intl                                                266                  266                  149                  149  78.0    %    97.8       % -19.8                    %                  913                  913                  913                  478                  478 *          *               *
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  541                  541                  384                  384  40.9    %    48.6       %  -7.7                    %                1,881                1,881                1,881                1,291                1,291  45.7    %    53.0       %  -7.3                    %
   IMBRUVICA
-------------------------------------
   US                                                  318                  318                  436                  436 -27.0    %   -27.0       %     -                  1,390                1,390                1,390                1,747                1,747 -20.4    %   -20.4       %     -  
   Intl                                                547                  547                  626                  626 -12.5    %    -2.0       % -10.5                    %                2,394                2,394                2,394                2,622                2,622  -8.7    %     1.0       %  -9.7                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  866                  866                1,062                1,062 -18.5    %   -12.3       %  -6.2                    %                3,784                3,784                3,784                4,369                4,369 -13.4    %    -7.6       %  -5.8                    %
   ZYTIGA / abiraterone acetate
-------------------------------------
   US                                                   20                   20                   23                   23 -14.3    %   -14.3       %     -                     74                   74                   74                  119                  119 -37.8    %   -37.8       %     -  
   Intl                                                250                  250                  525                  525 -52.4    %   -44.8       %  -7.6                    %                1,696                1,696                1,696                2,178                2,178 -22.1    %   -12.3       %  -9.8                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  270                  270                  548                  548 -50.8    %   -43.6       %  -7.2                    %                1,770                1,770                1,770                2,297                2,297 -22.9    %   -13.6       %  -9.3                    %
   OTHER ONCOLOGY
-------------------------------------
   US                                                  106                  106                   34                   34 *          *                   -                    289                  289                  289                  110                  110 *          *                   -  
   Intl                                                 63                   63                  106                  106 -41.1    %   -33.1       %  -8.0                    %                  283                  283                  283                  458                  458 -38.3    %   -31.6       %  -6.7                    %
                                      -------------------- -------------------- -------------------- --------------------                                                       -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                  168                  168                  140                  140  20.6    %    26.7       %  -6.1                    %                  571                  571                  571                  568                  568   0.6    %     6.0       %  -5.4                    %
 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                             REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                                                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
            FOURTH QUARTER                                                                                                    FOURTH QUARTER                                                                                                                                                                            TWELVE MONTHS
------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                  % Change                                                                                                             % Change
                                                                                                                                     ------------------------------------------------------------------------------------------                                                                                                                          ------------------------------------------------------------------------------------------
                                   2022                        2021                     Reported                     Operational (1)                    Currency                              2022                        2021                     Reported                     Operational (1)                    Currency
                                                           ------------------------------                       -------------------- ------------------------------  ------------------------------  ------------------------------                                            ------------------------------                       -------------------- ------------------------------  ------------------------------  ------------------------------
PULMONARY HYPERTENSION
-------------------------------------
US                                               610                  587                  587        3.9                    %        3.9                    %          -              2,346                2,365                2,365       -0.8                    %       -0.8                    %          -  
Intl                                             261                  264                  264       -1.3                    %       13.5                    %      -14.8                    %            1,071                1,085                1,085       -1.3                    %       11.2                    %      -12.5                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
WW                                               870                  851                  851        2.3                    %        6.9                    %       -4.6                    %            3,417                3,450                3,450       -1.0                    %        3.0                    %       -4.0                    %
   OPSUMIT
-------------------------------------
   US                                            305                  286                  286        7.0                    %        7.0                    %          -              1,132                1,147                1,147       -1.3                    %       -1.3                    %          -  
   Intl                                          156                  162                  162       -3.7                    %       11.0                    %      -14.7                    %              651                  672                  672       -3.2                    %        9.3                    %      -12.5                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                            461                  448                  448        3.1                    %        8.4                    %       -5.3                    %            1,783                1,819                1,819       -2.0                    %        2.6                    %       -4.6                    %
   UPTRAVI
-------------------------------------
   US                                            280                  264                  264        6.3                    %        6.3                    %          -              1,104                1,056                1,056        4.5                    %        4.5                    %          -  
   Intl                                           56                   46                   46       20.4                    %       33.3                    %      -12.9                    %              218                  181                  181       20.4                    %       32.4                    %      -12.0                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                            336                  310                  310        8.4                    %       10.3                    %       -1.9                    %            1,322                1,237                1,237        6.9                    %        8.6                    %       -1.7                    %
   OTHER PULMONARY HYPERTENSION
-------------------------------------
   US                                             24                   38                   38      -35.5                    %      -35.5                    %          -                110                  163                  163      -32.3                    %      -32.3                    %          -  
   Intl                                           48                   56                   56      -12.2                    %        4.4                    %      -16.6                    %              202                  232                  232      -12.8                    %        0.3                    %      -13.1                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                             73                   94                   94      -21.7                    %      -11.8                    %       -9.9                    %              313                  395                  395      -20.8                    %      -13.1                    %       -7.7                    %
CARDIOVASCULAR / METABOLISM / OTHER
-------------------------------------
US                                               776                  813                  813       -4.4                    %       -4.4                    %          -              3,042                3,192                3,192       -4.7                    %       -4.7                    %          -  
Intl                                             194                  200                  200       -3.4                    %        5.7                    %       -9.1                    %              845                  927                  927       -8.9                    %       -1.7                    %       -7.2                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
WW                                               971                1,013                1,013       -4.2                    %       -2.4                    %       -1.8                    %            3,887                4,119                4,119       -5.6                    %       -4.0                    %       -1.6                    %
   XARELTO
-------------------------------------
   US                                            667                  644                  644        3.4                    %        3.4                    %          -              2,473                2,438                2,438        1.4                    %        1.4                    %          -  
   Intl                                            -                    -                    -          -            -            -                  -                    -                    -          -            -            -  
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                            667                  644                  644        3.4                    %        3.4                    %          -              2,473                2,438                2,438        1.4                    %        1.4                    %          -  
   INVOKANA / INVOKAMET
-------------------------------------
   US                                             29                   59                   59      -51.3                    %      -51.3                    %          -                193                  308                  308      -37.4                    %      -37.4                    %          -  
   Intl                                           62                   60                   60        2.3                    %       11.2                    %       -8.9                    %              255                  254                  254        0.1                    %        7.3                    %       -7.2                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                             91                  120                  120      -24.1                    %      -19.6                    %       -4.5                    %              448                  563                  563      -20.4                    %      -17.2                    %       -3.2                    %
   OTHER
-------------------------------------
   US                                             81                  110                  110      -25.7                    %      -25.7                    %          -                376                  446                  446      -15.5                    %      -15.5                    %          -  
   Intl                                          132                  140                  140       -5.9                    %        3.3                    %       -9.2                    %              590                  673                  673      -12.3                    %       -5.1                    %       -7.2                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
   WW                                            213                  250                  250      -14.6                    %       -9.4                    %       -5.2                    %              966                1,119                1,119      -13.6                    %       -9.3                    %       -4.3                    %
                                                                                                                                        
TOTAL PHARMACEUTICAL
-------------------------------------
US                                             7,375                7,418                7,418       -0.6                    %       -0.6                    %          -             28,604               27,954               27,954        2.3                    %        2.3                    %          -  
Intl                                           5,788                6,799                6,799      -14.9                    %       -4.5                    %      -10.4                    %           23,959               23,726               23,726        1.0                    %       11.9                    %      -10.9                    %
                                      -------------------- -------------------- ---------- -------------------- --------------------                                                                                                 -------------------- -------------------- -------------------- ---------- -------------------- --------------------
WW                                                       $                    $     13,163               14,217               14,217       -7.4                    %       -2.5                    %       -4.9                    %                    $                    $                    $     52,563               51,680               51,680        1.7                    %        6.7                    %       -5.0                    %
                                      ==================== ==================== ========== ==================== ====================                                                                                                 ==================== ==================== ==================== ========== ==================== ====================
                                                                                                                                        
------------------------------------- -------------------- ---------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------- -------------------- ---------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------
                                                                                                                                   
REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)                                                         REPORTED SALES vs. PRIOR PERIOD ($MM)                                                       REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)                                                         REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
            FOURTH QUARTER                                                                                                  FOURTH QUARTER                                                                                                   TWELVE MONTHS                         TWELVE MONTHS                                                                                TWELVE MONTHS
------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        % Change                                                                                                                         % Change
                                                                                                                                                      --------------------------------------------------------------------                                                                                                                                                            --------------------------------------------------------------------
MEDTECH SEGMENT (2,3,5)                                2022                               2022                        2021               Reported          Operational (1)               Currency                                                                2022                        2021               Reported          Operational (1)               Currency
------------------------------------- ------------------------------------- ------------------------------                       -------------------- -------------------  -------------------  ------------------------------                                                                              ------------------------------                       -------------------- -------------------  -------------------  ------------------------------
                                                                                                                                          
INTERVENTIONAL SOLUTIONS
-------------------------------------
US                                                                        $                    $        603                  483                  483       24.9         %       24.9         %          -                                       $                                     $                    $      2,169                1,836                1,836       18.2         %       18.2         %          -  
Intl                                                              495                  536                  536       -7.6         %        6.2         %      -13.8                    %                                              2,131                2,135                2,135       -0.2         %        9.9         %      -10.1                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
WW                                                              1,098                1,019                1,019        7.8         %       15.1         %       -7.3                    %                                              4,300                3,971                3,971        8.3         %       13.7         %       -5.4                    %
ORTHOPAEDICS
-------------------------------------
US                                                              1,385                1,305                1,305        6.1         %        6.1         %          -                                                5,321                5,126                5,126        3.8         %        3.8         %          -  
Intl                                                              763                  851                  851      -10.4         %        0.8         %      -11.2                    %                                              3,267                3,462                3,462       -5.6         %        3.4         %       -9.0                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
WW                                                              2,148                2,155                2,155       -0.4         %        4.0         %       -4.4                    %                                              8,587                8,588                8,588        0.0         %        3.7         %       -3.7                    %
   HIPS
-------------------------------------
   US                                                             250                  227                  227        9.7         %        9.7         %          -                                                  943                  878                  878        7.3         %        7.3         %          -  
   Intl                                                           135                  151                  151      -10.4         %        0.4         %      -10.8                    %                                                571                  602                  602       -5.1         %        3.6         %       -8.7                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
   WW                                                             385                  378                  378        1.7         %        6.0         %       -4.3                    %                                              1,514                1,480                1,480        2.3         %        5.8         %       -3.5                    %
   KNEES
-------------------------------------
   US                                                             231                  208                  208       11.8         %       11.8         %          -                                                  851                  787                  787        8.2         %        8.2         %          -  
   Intl                                                           122                  135                  135       -9.5         %        1.2         %      -10.7                    %                                                508                  538                  538       -5.7         %        3.1         %       -8.8                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
   WW                                                             354                  342                  342        3.4         %        7.6         %       -4.2                    %                                              1,359                1,325                1,325        2.6         %        6.1         %       -3.5                    %
   TRAUMA
-------------------------------------
   US                                                             470                  467                  467        0.7         %        0.7         %          -                                                1,882                1,819                1,819        3.5         %        3.5         %          -  
   Intl                                                           240                  261                  261       -7.9         %        3.5         %      -11.4                    %                                                989                1,066                1,066       -7.2         %        2.6         %       -9.8                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
   WW                                                             710                  728                  728       -2.4         %        1.7         %       -4.1                    %                                              2,871                2,885                2,885       -0.5         %        3.1         %       -3.6                    %
   SPINE, SPORTS & OTHER
-------------------------------------
   US                                                             434                  403                  403        7.5         %        7.5         %          -                                                1,645                1,642                1,642        0.2         %        0.2         %          -  
   Intl                                                           265                  304                  304      -12.9         %       -1.5         %      -11.4                    %                                              1,198                1,256                1,256       -4.6         %        4.3         %       -8.9                    %
                                      ------------------------------------- -------------------- ---------- -------------------- --------------------                                                                           ------------------------------------- ------------------------------------- -------------------- ---------- -------------------- --------------------
   WW                                                             699                  708                  708       -1.3         %        3.6         %       -4.9                    %                                              2,843                2,898                2,898       -1.9         %        1.9         %       -3.8                    %
 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)                                                                                                                                                                                               REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
            FOURTH QUARTER                                                                                                                        FOURTH QUARTER                                                                                                                                                                                                                       TWELVE MONTHS
------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        % Change                                                                                                                             % Change
                                                                                                                                               ------------------------------------------------------------------------------------------------------------------------                                                                                                                                    --------------------------------------------------------------------------------------------------------------
                                        2022                             2021                          Reported                               Operational (1)                              Currency                                        2022                             2021                          Reported                               Operational (1)                         Currency
                                                           ----------------------------------------                       -------------------- ----------------------------------------  ----------------------------------------  ----------------------------------------                                            ----------------------------------------                       -------------------- ----------------------------------------  ----------------------------------------  ------------------------------
SURGERY
-------------------------------------
US                                                       1,000                  986                  986                  1.5                    %                  1.5                    %                    -                        3,897                3,867                3,867                  0.8                    %                  0.8                    %          -  
Intl                                                     1,383                1,527                1,527                 -9.4                    %                  1.4                    %                -10.8                    %                      5,793                5,945                5,945                 -2.6                    %                  5.7                    %       -8.3                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       2,384                2,513                2,513                 -5.1                    %                  1.4                    %                 -6.5                    %                      9,690                9,812                9,812                 -1.2                    %                  3.8                    %       -5.0                    %
   ADVANCED
-------------------------------------
   US                                                      456                  457                  457                 -0.2                    %                 -0.2                    %                    -                        1,784                1,761                1,761                  1.3                    %                  1.3                    %          -  
   Intl                                                    653                  735                  735                -11.1                    %                 -0.4                    %                -10.7                    %                      2,785                2,861                2,861                 -2.6                    %                  5.3                    %       -7.9                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                    1,109                1,192                1,192                 -7.0                    %                 -0.3                    %                 -6.7                    %                      4,569                4,622                4,622                 -1.1                    %                  3.8                    %       -4.9                    %
   GENERAL
-------------------------------------
   US                                                      544                  528                  528                  3.1                    %                  3.1                    %                    -                        2,113                2,105                2,105                  0.4                    %                  0.4                    %          -  
   Intl                                                    731                  793                  793                 -7.8                    %                  3.0                    %                -10.8                    %                      3,008                3,085                3,085                 -2.5                    %                  6.2                    %       -8.7                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                    1,275                1,321                1,321                 -3.5                    %                  3.0                    %                 -6.5                    %                      5,121                5,190                5,190                 -1.3                    %                  3.8                    %       -5.1                    %
VISION
-------------------------------------
US                                                         456                  443                  443                  3.1                    %                  3.1                    %                    -                        1,990                1,857                1,857                  7.2                    %                  7.2                    %          -  
Intl                                                       689                  728                  728                 -5.4                    %                  5.9                    %                -11.3                    %                      2,859                2,831                2,831                  1.0                    %                 11.1                    %      -10.1                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       1,145                1,171                1,171                 -2.2                    %                  4.8                    %                 -7.0                    %                      4,849                4,688                4,688                  3.4                    %                  9.5                    %       -6.1                    %
   CONTACT LENSES / OTHER
-------------------------------------
   US                                                      343                  316                  316                  8.6                    %                  8.6                    %                    -                        1,522                1,398                1,398                  8.9                    %                  8.9                    %          -  
   Intl                                                    489                  518                  518                 -5.6                    %                  7.2                    %                -12.8                    %                      2,022                2,043                2,043                 -1.0                    %                 10.1                    %      -11.1                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                      831                  833                  833                 -0.2                    %                  7.7                    %                 -7.9                    %                      3,543                3,440                3,440                  3.0                    %                  9.6                    %       -6.6                    %
   SURGICAL
-------------------------------------
   US                                                      113                  126                  126                -10.7                    %                -10.7                    %                    -                          468                  459                  459                  2.0                    %                  2.0                    %          -  
   Intl                                                    200                  211                  211                 -5.0                    %                  2.9                    %                 -7.9                    %                        837                  788                  788                  6.2                    %                 13.7                    %       -7.5                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
   WW                                                      314                  338                  338                 -7.1                    %                 -2.2                    %                 -4.9                    %                      1,306                1,248                1,248                  4.6                    %                  9.4                    %       -4.8                    %
                                                                         
TOTAL MEDTECH
-------------------------------------
US                                                       3,445                3,216                3,216                  7.1                    %                  7.1                    %                    -                       13,377               12,686               12,686                  5.4                    %                  5.4                    %          -  
Intl                                                     3,331                3,643                3,643                 -8.6                    %                  2.9                    %                -11.5                    %                     14,050               14,374               14,374                 -2.3                    %                  6.9                    %       -9.2                    %
                                      -------------------- -------------------- -------------------- -------------------- --------------------                                                                                                                               -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
WW                                                       $                    $                6,776                6,859                6,859                 -1.2                    %                  4.9                    %                 -6.1                    %                    $                    $                    $               27,427               27,060               27,060                  1.4                    %                  6.2                    %       -4.8                    %
                                      ==================== ==================== ==================== ==================== ====================                                                                                                                               ==================== ==================== ==================== ==================== ==================== ====================
                                                                         
------------------------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------------------
                                                                         
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
                                                                         
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
                                                                                                                                                                                                                                     Supplemental Sales Reconciliation (Unaudited)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                     (Dollars in Millions)
                                                                                                                                                        
----------------------------------------- -------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
              FOURTH QUARTER                 FOURTH QUARTER                                                                                                                 FOURTH QUARTER                                                                                                                                                                                                                              TWELVE MONTHS
----------------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                          Percent Change                                                                                                                                                 Percent Change
----------------------------------------- -------------------- ------------------------------  -------------------- -------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------                             ------------------------------  -------------------- -------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------
                   2022                           2022                       2022                        2021                         Total                          Operations                         Currency                            2022                        2021                         Total                          Operations                         Currency
----------------------------------------- -------------------- ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------                       ------------------------------  -------------------- -------------------- -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------
                                                                                                                                                        
Pharmaceutical
  U.S.                                                       $                    $      7,375                7,418                7,418                 (0.6       (0.6                    )                    %       (0.6                    )                    -          -                      $                    $     28,604               27,954               27,954                  2.3        2.3                      %        2.3                      -          -  
  International                                    5,788                6,799                6,799                (14.9      (14.9                    )                 (4.5       (4.5                    )                (10.4      (10.4                    )         23,959               23,726               23,726                  1.0        1.0                   11.9       11.9                  (10.9      (10.9                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide                                         13,163               14,217               14,217                 (7.4       (7.4                    )                 (2.5       (2.5                    )                 (4.9       (4.9                    )         52,563               51,680               51,680                  1.7        1.7                    6.7        6.7                   (5.0       (5.0                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
COVID-19 Vaccine
  U.S.                                                 0                  213                  213                    *                               *                    *                               *                    -          -              120                  634                  634                (81.1      (81.1                    )                (81.1      (81.1                    )                    -          -  
  International                                      689                1,405                1,405                (50.9      (50.9                    )                (45.0      (45.0                    )                 (5.9       (5.9                    )          2,059                1,751                1,751                 17.6       17.6                   32.1       32.1                  (14.5      (14.5                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide                                            689                1,619                1,619                (57.4      (57.4                    )                (52.2      (52.2                    )                 (5.2       (5.2                    )          2,179                2,385                2,385                 (8.6       (8.6                    )                  2.0        2.0                  (10.6      (10.6                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
Pharmaceutical excluding COVID-19 Vaccine
  U.S.                                             7,375                7,205                7,205                  2.4        2.4                    2.4        2.4                      -          -           28,484               27,320               27,320                  4.3        4.3                    4.3        4.3                      -          -  
  International                                    5,099                5,394                5,394                 (5.5       (5.5                    )                  6.0        6.0                  (11.5      (11.5                    )         21,900               21,975               21,975                 (0.3       (0.3                    )                 10.3       10.3                  (10.6      (10.6                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide                                         12,474               12,599               12,599                 (1.0       (1.0                    )                  3.9        3.9                   (4.9       (4.9                    )         50,384               49,295               49,295                  2.2        2.2                    6.9        6.9                   (4.7       (4.7                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
Worldwide
  U.S.                                            12,516               12,163               12,163                  2.9        2.9                    2.9        2.9                      -          -           48,580               47,156               47,156                  3.0        3.0                    3.0        3.0                      -          -  
  International                                   11,190               12,641               12,641                (11.5      (11.5                    )                 (1.1       (1.1                    )                (10.4      (10.4                    )         46,363               46,619               46,619                 (0.6       (0.6                    )                  9.1        9.1                   (9.7       (9.7                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide                                         23,706               24,804               24,804                 (4.4       (4.4                    )                  0.9        0.9                   (5.3       (5.3                    )         94,943               93,775               93,775                  1.3        1.3                    6.1        6.1                   (4.8       (4.8                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
COVID-19 Vaccine
  U.S.                                                 0                  213                  213                    *                               *                    *                               *                    -          -              120                  634                  634                (81.1      (81.1                    )                (81.1      (81.1                    )                    -          -  
  International                                      689                1,405                1,405                (50.9      (50.9                    )                (45.0      (45.0                    )                 (5.9       (5.9                    )          2,059                1,751                1,751                 17.6       17.6                   32.1       32.1                  (14.5      (14.5                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide                                            689                1,619                1,619                (57.4      (57.4                    )                (52.2      (52.2                    )                 (5.2       (5.2                    )          2,179                2,385                2,385                 (8.6       (8.6                    )                  2.0        2.0                  (10.6      (10.6                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
Worldwide
  U.S.                                            12,516               11,950               11,950                  4.7        4.7                    4.7        4.7                      -          -           48,460               46,522               46,522                  4.2        4.2                    4.2        4.2                      -          -  
  International                                   10,501               11,236               11,236                 (6.5       (6.5                    )                  4.4        4.4                  (10.9      (10.9                    )         44,304               44,868               44,868                 (1.3       (1.3                    )                  8.2        8.2                   (9.5       (9.5                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Worldwide excluding COVID-19 Vaccine                         $                    $     23,017               23,186               23,186                 (0.7       (0.7                    )                    %        4.6                   (5.3       (5.3                    )                    $                    $     92,764               91,390               91,390                  1.5        1.5                      %        6.2                   (4.7       (4.7                    )
                                          -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
                                                                                                                                                        
Note: Columns and rows within tables may not add due to rounding
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                                                                                                                                                                                     Q4 QTD - Income Before Tax by Segment*
                                                                                                                                                                                                                                     Dollars in Millions
                                                                                                                                                                                                    
               Consumer Health(1)                                                 Consumer Health(1)                                                                      Pharmaceutical(1)                                                                           MedTech                                                                              Unallocated                                                                          Consumer Health                                                                        Worldwide Total
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Separation Costs
------------------------------------------------ --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------
                      2022                                     2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021
------------------------------------------------ ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------
                                                                                                                                                                                                    
Reported Income Before Tax by Segment$                  651                    442        442                  3,308      3,308                  4,306      4,306                    865        865                    575        575                   (153       (153 )                                    (420       (420 )                                    (470       (470 )                                     (67        (67 )                                   4,201      4,201                  4,836      4,836  
% to Sales                                             17.3                    %                 11.9       11.9                    %                 25.1       25.1                    %                 30.3       30.3                    %                 12.8       12.8                    %                  8.4        8.4                    %                 -0.6       -0.6                    %                 -1.7       -1.7                    %                 -2.0       -2.0                    %                 -0.3       -0.3                    %                 17.7       17.7                    %                 19.5       19.5                    %
                                                                                                                                                                                                    
Intangible asset amortization expense                    84                    100        100                    717        717                    761        761                    260        260                    260        260                      -          -                      -          -                      -          -                      -          -                  1,061      1,061                  1,121      1,121  
                                                                                                                                                                                                    
In-process research and development                       -                      -          -                    173        173                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                    173        173                      -          -  
                                                                                                                                                                                                    
Litigation related                                       72                    122        122                     61         61                    (35        (35 )                                     129        129                    187        187                      -          -                      -          -                      -          -                      -          -                    262        262                    274        274  
                                                                                                                                                                                                    
Loss/(gain) on securities                                 -                      1          1                     23         23                   (237       (237 )                                     (17        (17 )                                      38         38                      -          -                      -          -                      -          -                      -          -                      6          6                   (198       (198 )
                                                                                                                                                                                                    
Restructuring related                                    21                     28         28                     31         31                     22         22                     88         88                     90         90                      -          -                      -          -                      -          -                      -          -                    140        140                    140        140  
                                                                                                                                                                                                    
Acquisition, integration and divestiture related          -                      -          -                   (104       (104 )                                       5          5                    300        300                     21         21                      -          -                      -          -                      -          -                      -          -                    196        196                     26         26  
                                                                                                                                                                                                    
Medical Device Regulation                                 -                      -          -                      -          -                      -          -                     88         88                     73         73                      -          -                      -          -                      -          -                      -          -                     88         88                     73         73  
                                                                                                                                                                                                    
COVID-19 Vaccine related costs                            -                      -          -                    821        821                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                    821        821                      -          -  
                                                                                                                                                                                                    
Consumer Health separation costs                          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                    470        470                     67         67                    470        470                     67         67  
                                                                                                                                                                                                    
Other                                                     -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -  
                                                                                                                                                                                                    
------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
Adjusted Income Before Tax by Segment$                  828                    693        693                  5,030      5,030                  4,822      4,822                  1,713      1,713                  1,244      1,244                   (153       (153 )                                    (420       (420 )                                       -          -                      -          -                  7,418      7,418                  6,339      6,339  
                                                 ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
% to Sales                                             22.0                    %                 18.6       18.6                    %                 38.2       38.2                    %                 33.9       33.9                    %                 25.3       25.3                    %                 18.1       18.1                    %                 -0.6       -0.6                    %                 -1.7       -1.7                    %                  0.0        0.0                    %                  0.0        0.0                    %                 31.3       31.3                    %                 25.6       25.6                    %
                                                                                                                                                                                                    
                                                                                                                                                                                                    
                                                                                                                                                                                                    
(1) Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
                                                                                                                                                                                                    
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                                                                                                                                                                                     Q4 YTD - Income Before Tax by Segment*
                                                                                                                                                                                                                                     Dollars in Millions
                 Consumer Health                          Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health                                      Consumer Health
                Separation Costs                         Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs           Separation Costs          Separation Costs                                     Separation Costs
------------------------------------------------ ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  --------------------
               Consumer Health(1)                                                 Consumer Health(1)                                                                      Pharmaceutical(1)                                                                           MedTech                                                                              Unallocated                                      
------------------------------------------------ --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------                          --------------------------------------------------------------------------------
                      2022                                     2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021                              2022                              2021
------------------------------------------------ ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------                       ------------------------------
                                                                                                                                                                                                    
Reported Income Before Tax by Segment$                2,930                  1,573      1,573                 15,901     15,901                 17,969     17,969                  4,607      4,607                  4,373      4,373                   (624       (624 )                                  (1,072     (1,072 )                                  (1,089     (1,089 )                                     (67        (67 )                                  21,725     21,725                 22,776     22,776  
% to Sales                                             19.6                    %                 10.5       10.5                    %                 30.3       30.3                    %                 34.8       34.8                    %                 16.8       16.8                    %                 16.2       16.2                    %                 -0.7       -0.7                    %                 -1.1       -1.1                    %                 -1.1       -1.1                    %                 -0.1       -0.1                    %                 22.9       22.9                    %                 24.3       24.3                    %
                                                                                                                                                                                                    
Intangible asset amortization expense                   361                    414        414                  2,911      2,911                  3,258      3,258                  1,033      1,033                  1,025      1,025                      -          -                      -          -                      -          -                      -          -                  4,305      4,305                  4,697      4,697  
                                                                                                                                                                                                    
In-process research and development                       -                      -          -                    783        783                      -          -                      -          -                    900        900                      -          -                      -          -                      -          -                      -          -                    783        783                    900        900  
                                                                                                                                                                                                    
Litigation related                                      150                  1,603      1,603                    104        104                    640        640                    612        612                     85         85                      -          -                      -          -                      -          -                      -          -                    866        866                  2,328      2,328  
                                                                                                                                                                                                    
Loss/(gain) on securities                                 -                    (18        (18 )                                     696        696                   (486       (486 )                                      (6         (6 )                                     (29        (29 )                                       -          -                      -          -                      -          -                      -          -                    690        690                   (533       (533 )
                                                                                                                                                                                                    
Restructuring related                                    91                    119        119                     63         63                     76         76                    309        309                    278        278                      -          -                      -          -                      -          -                      -          -                    463        463                    473        473  
                                                                                                                                                                                                    
Acquisition, integration and divestiture related          -                      -          -                   (104       (104 )                                    (562       (562 )                                     300        300                     84         84                      -          -                      -          -                      -          -                      -          -                    196        196                   (478       (478 )
                                                                                                                                                                                                    
Medical Device Regulation                                 -                      -          -                      -          -                      -          -                    296        296                    234        234                      -          -                      -          -                      -          -                      -          -                    296        296                    234        234  
                                                                                                                                                                                                    
COVID-19 Vaccine related costs                            -                      -          -                  1,474      1,474                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                      -          -                  1,474      1,474                      -          -  
                                                                                                                                                                                                    
Consumer Health separation costs                          -                      -                               -                    -          -                      -          -                      -          -                      -          -                      -          -                      -          -                  1,089      1,089                     67         67                  1,089      1,089                     67         67  
                                                                                                                                                                                                    
Other                                                     -                      -          -                      -          -                      -          -                      -          -                      -          -                     (7         (7 )                                       -          -                      -          -                      -          -                     (7         (7 )                                       -          -  
                                                                                                                                                                                                    
------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------
Adjusted Income Before Tax by Segment$                3,532                  3,691      3,691                 21,828     21,828                 20,895     20,895                  7,151      7,151                  6,950      6,950                   (631       (631 )                                  (1,072     (1,072 )                                       -          -                      -          -                 31,880     31,880                 30,464     30,464  
                                                 ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
% to Sales                                             23.6                    %                 24.5       24.5                    %                 41.5       41.5                    %                 40.4       40.4                    %                 26.1       26.1                    %                 25.7       25.7                    %                 -0.7       -0.7                    %                 -1.1       -1.1                    %                  0.0        0.0                    %                  0.0        0.0                    %                 33.6       33.6                    %                 32.5       32.5                    %
                                                                                                                                                                                                    
                                                                                                                                                                                                    
                                                                                                                                                                                                    
(1) Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
                                                                                                                                                                                                    
                                                                                                                                                                                                                                     Johnson & Johnson and Subsidiaries
                                                                                                                                                                                                                                     GAAP to Non-GAAP Reconciliation
                                                                                                                                                                                                                                     $ in Millions
                                                                                                                                                                                                                                                                         
Quarter to Date
            Consumer Health                    Consumer Health             Consumer Health               Consumer Health              Consumer Health               Consumer Health              Consumer Health               Consumer Health                 Consumer Health                  Consumer Health                 Consumer Health                  Consumer Health             Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health            Consumer Health            Consumer Health           Consumer Health            Consumer Health
            separation tax                     separation tax              separation tax                separation tax               separation tax                separation tax               separation tax                separation tax                  separation tax                   separation tax                  separation tax                   separation tax              separation tax             separation tax            separation tax             separation tax            separation tax             separation tax             separation tax             separation tax            separation tax             separation tax
             related costs                      related costs               related costs                 related costs                related costs                 related costs                related costs                 related costs                   related costs                    related costs                   related costs                    related costs               related costs              related costs             related costs              related costs             related costs              related costs              related costs              related costs             related costs              related costs
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  -------------------- ------------------------------
            Fourth Quarter                     Fourth Quarter                In-process                    In-process                   In-process                    In-process                   In-process                    In-process             Acquisition, integration and     Acquisition, integration and    Acquisition, integration and     Acquisition, integration and       (Loss)/gain on             (Loss)/gain on           COVID-19 Vaccine           COVID-19 Vaccine          COVID-19 Vaccine           COVID-19 Vaccine            Consumer Health            Consumer Health           Tax legislation
                                                                            research and                  research and                 research and                  research and                 research and                  research and               divestiture related (1)          divestiture related (1)         divestiture related (1)          divestiture related (1)           securities                 securities               Related Costs              Related Costs             Related Costs              Related Costs            separation costs           separation costs            and other tax
                                                                             development                   development                  development                   development                  development                   development                                                                                                                                                                                                                                                                                                                                                                          related
                                                                      ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  --------------------
              Jan 1, 2023                        Jan 1, 2023              Intangible asset              Intangible asset            Litigation related            Litigation related              Restructuring       Restructuring                   Restructuring                  Medical Device    Medical Device           Medical Device                   Medical Device                   Other           Other           Other                Other           Other                      Other                   Jan 1, 2023                Jan 1, 2023
                 GAAP                               GAAP                    amortization                  amortization                                                                               related             related                         related                       Regulation        Regulation               Regulation                       Regulation                                                                                                                                              Non-GAAP                   Non-GAAP
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ------------- ------------------------------------------------  -------------- -------------------- ---------------------------- ----------------------------------  -------------------- ---------- -------------------- -------------------- ---------- ----------------------------------------  ----------- ----------------------------------------
Cost of products sold                                    $      7,765                   (1,060       (1,060 )                                         (36                               (36                      (36                                (36                          (36            (36 )                                             (33                                 (33                  (33                             (33                  (33        (33 )                                    (160        (160 )                                      (4         (4 )                                       -          -                      -          -                      -          -                  6,472      6,472  
Selling, marketing and admin expenses        6,512                       (9                                (9                       (9                                (9                       (9                                 (9                           (9                                  (9                           (9                                  (9                   (9                              (9                   (9         (9 )                                       -           -                    (43        (43 )                                   6,460                           6,460                6,460                           6,460                6,460                           6,460                6,460      6,460  
Research and development expense             3,841                        -                                 -                        -                                 -                        -                                  -                            -                                   -                            -              -                    (46                             (46                  (46        (46 )                                    (114        (114 )                                       -          -                  3,681                           3,681                3,681                           3,681                3,681                           3,681                3,681      3,681  
Other (Income) / Expense                     1,207                       (1           (1 )                                        (262         (262 )                                         (20                                (20                          (20            (20 )                                            (196           (196 )                                      (6         (6 )                                    (547                            (547                 (547        (547 )                                    (423       (423 )                                       -          -                      -                               -                    -          -                   (248       (248 )
In-process research and development            173                     (173                              (173                     (173                              (173                     (173          (173 )                                               -                                   -                            -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Restructuring                                   84                      (84                               (84                      (84                               (84                      (84                                (84                          (84            (84 )                                               -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Provision for taxes on income                  681                      165          165                        (36          (36 )                                          40            40                             21             21                              5              5                      2          2                     17         17                    199         199                     94         94                    (35        (35 )                                      47         47                      -          -                  1,200      1,200  
Net Earnings                                 3,520                      896          896                        298          298                        133           133                            119            119                            191            191                      4          4                     71         71                    622         622                    376        376                     35         35                    (47        (47 )                                       -          -                  6,218      6,218  
                                                                                                                                                                                                                                                                   
            Consumer Health                    Consumer Health             Consumer Health               Consumer Health              Consumer Health               Consumer Health              Consumer Health               Consumer Health                 Consumer Health                  Consumer Health                 Consumer Health                  Consumer Health             Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health            Consumer Health            Consumer Health           Consumer Health            Consumer Health
            separation tax                     separation tax              separation tax                separation tax               separation tax                separation tax               separation tax                separation tax                  separation tax                   separation tax                  separation tax                   separation tax              separation tax             separation tax            separation tax             separation tax            separation tax             separation tax             separation tax             separation tax            separation tax             separation tax
             related costs                      related costs               related costs                 related costs                related costs                 related costs                related costs                 related costs                   related costs                    related costs                   related costs                    related costs               related costs              related costs             related costs              related costs             related costs              related costs              related costs              related costs             related costs              related costs
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  -------------------- ------------------------------
            Fourth Quarter                     Fourth Quarter                In-process                    In-process                   In-process                    In-process                   In-process                    In-process             Acquisition, integration and     Acquisition, integration and    Acquisition, integration and     Acquisition, integration and       (Loss)/gain on             (Loss)/gain on           COVID-19 Vaccine           COVID-19 Vaccine          COVID-19 Vaccine           COVID-19 Vaccine            Consumer Health            Consumer Health         Tax legislation and
                                                                            research and                  research and                 research and                  research and                 research and                  research and                 divestiture related              divestiture related             divestiture related              divestiture related             securities                 securities               Related Costs              Related Costs             Related Costs              Related Costs            separation costs           separation costs          other tax related
                                                                             development                   development                  development                   development                  development                   development
                                                                      ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  --------------------
              Jan 2, 2022                        Jan 2, 2022              Intangible asset              Intangible asset            Litigation related            Litigation related              Restructuring       Restructuring                   Restructuring                  Medical Device    Medical Device           Medical Device                   Medical Device                   Other           Other           Other                Other           Other                      Other                   Jan 2, 2022                Jan 2, 2022
                 GAAP                               GAAP                    amortization                  amortization                                                                               related             related                         related                       Regulation        Regulation               Regulation                       Regulation                                                                                                                                              Non-GAAP                   Non-GAAP
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ------------- ------------------------------------------------  -------------- -------------------- ---------------------------- ----------------------------------  -------------------- ---------- -------------------- -------------------- ---------- ----------------------------------------  ----------- ----------------------------------------
Cost of products sold                                    $      7,955                   (1,111       (1,111 )                                         (21                               (21                      (21                                (21                          (21            (21 )                                             (26                                 (26                  (26                             (26                  (26        (26 )                                   6,797                            6,797                6,797                           6,797                6,797                           6,797                6,797                           6,797                6,797                           6,797                6,797      6,797  
Selling, marketing and admin expenses        7,154                       (7                                (7                       (7                                (7                       (7                                 (7                           (7                                  (7                           (7                                  (7                   (7                              (7                   (7         (7 )                                   7,147                            7,147                7,147                           7,147                7,147                           7,147                7,147                           7,147                7,147                           7,147                7,147      7,147  
Research and development expense             4,720                        -                                 -                        -                                 -                        -                                  -                            -                                   -                            -              -                    (40                             (40                  (40        (40 )                                   4,680                            4,680                4,680                           4,680                4,680                           4,680                4,680                           4,680                4,680                           4,680                4,680      4,680  
Other (Income) / Expense                         9                      (10          (10 )                                        (274         (274 )                                         (36                                (36                          (36            (36 )                                             (26            (26 )                                     198        198                      -                               -                    -           -                    (67        (67 )                                       -          -                      -                               -                    -          -                   (206       (206 )
In-process research and development              -                        -                                 -                        -                                 -                        -             -                              -                                   -                            -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Restructuring                                   83                      (83                               (83                      (83                               (83                      (83                                (83                          (83            (83 )                                               -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Provision for taxes on income                  100                      162          162                         49           49                          -             -                             27             27                              6              6                    (89        (89 )                                      14         14                      -           -                     15         15                      -          -                    377        377                      -          -                    661        661  
Net Earnings                                 4,736                      959          959                        225          225                          -             -                            113            113                             20             20                   (109       (109 )                                      59         59                      -           -                     52         52                      -          -                   (377       (377 )                                       -          -                  5,678      5,678  
                                                                                                                                                                                                                                                                   
Year to Date
            Consumer Health                    Consumer Health             Consumer Health               Consumer Health              Consumer Health               Consumer Health              Consumer Health               Consumer Health                 Consumer Health                  Consumer Health                 Consumer Health                  Consumer Health             Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health            Consumer Health            Consumer Health           Consumer Health            Consumer Health
            separation tax                     separation tax              separation tax                separation tax               separation tax                separation tax               separation tax                separation tax                  separation tax                   separation tax                  separation tax                   separation tax              separation tax             separation tax            separation tax             separation tax            separation tax             separation tax             separation tax             separation tax            separation tax             separation tax
             related costs                      related costs               related costs                 related costs                related costs                 related costs                related costs                 related costs                   related costs                    related costs                   related costs                    related costs               related costs              related costs             related costs              related costs             related costs              related costs              related costs              related costs             related costs              related costs
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  -------------------- ------------------------------
             Twelve Months                      Twelve Months                In-process                    In-process                   In-process                    In-process                   In-process                    In-process             Acquisition, integration and     Acquisition, integration and    Acquisition, integration and     Acquisition, integration and       (Loss)/gain on             (Loss)/gain on           COVID-19 Vaccine           COVID-19 Vaccine          COVID-19 Vaccine           COVID-19 Vaccine            Consumer Health            Consumer Health           Tax legislation
                                                                            research and                  research and                 research and                  research and                 research and                  research and               divestiture related (1)          divestiture related (1)         divestiture related (1)          divestiture related (1)           securities                 securities               Related Costs              Related Costs             Related Costs              Related Costs            separation costs           separation costs            and other tax
                                                                             development                   development                  development                   development                  development                   development                                                                                                                                                                                                                                                                                                                                                                          related
                                                                      ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  --------------------
              Jan 1, 2023                        Jan 1, 2023              Intangible asset              Intangible asset            Litigation related            Litigation related              Restructuring       Restructuring                   Restructuring                  Medical Device    Medical Device           Medical Device                   Medical Device                   Other           Other           Other                Other           Other                      Other                   Jan 1, 2023                Jan 1, 2023
                 GAAP                               GAAP                    amortization                  amortization                                                                               related             related                         related                       Regulation        Regulation               Regulation                       Regulation                                                                                                                                              Non-GAAP                   Non-GAAP
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ------------- ------------------------------------------------  -------------- -------------------- ---------------------------- ----------------------------------  -------------------- ---------- -------------------- -------------------- ---------- ----------------------------------------  ----------- ----------------------------------------
Cost of products sold                                    $     31,089                   (4,292       (4,292 )                                         (82                               (82                      (82                                (82                          (82            (82 )                                            (109                                (109                 (109                            (109                 (109       (109 )                                    (456        (456 )                                      (4         (4 )                                  26,146                          26,146               26,146                          26,146               26,146                          26,146               26,146     26,146  
Selling, marketing and admin expenses       24,765                      (28                               (28                      (28                               (28                      (28                                (28                          (28                                 (28                          (28                                 (28                  (28                             (28                  (28        (28 )                                     (45                              (45                  (45        (45 )                                  24,692                          24,692               24,692                          24,692               24,692                          24,692               24,692     24,692  
Research and development expense            14,603                        -                                 -                        -                                 -                        -                                  -                            -                                   -                            -              -                   (159                            (159                 (159       (159 )                                    (304        (304 )                                  14,140                          14,140               14,140                          14,140               14,140                          14,140               14,140                          14,140               14,140     14,140  
Other (Income) / Expense                     1,871                      (13          (13 )                                        (866         (866 )                                         (60                                (60                          (60            (60 )                                            (196           (196 )                                    (690       (690 )                                    (714                            (714                 (714        (714 )                                  (1,040     (1,040 )                                       -          -                      7                               7                    7          7                 (1,701     (1,701 )
In-process research and development            783                     (783                              (783                     (783                              (783                     (783          (783 )                                               -                                   -                            -              -                      -          -                      -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Restructuring                                  321                     (321                              (321                     (321                              (321                     (321                               (321                         (321           (321 )                                               -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Provision for taxes on income                3,784                      667          667                       (125         (125 )                                         178           178                             81             81                              5              5                    166        166                     56         56                    360         360                    206        206                   (494       (494 )                                     (40        (40 )                                      (2         (2 )                                   4,842      4,842  
Net Earnings                                17,941                    3,638        3,638                        991          991                        605           605                            382            382                            191            191                    524        524                    240        240                  1,114       1,114                    883        883                    494        494                     40         40                     (5         (5 )                                  27,038     27,038  
                                                                                                                                                                                                                                                                   
            Consumer Health                    Consumer Health             Consumer Health               Consumer Health              Consumer Health               Consumer Health              Consumer Health               Consumer Health                 Consumer Health                  Consumer Health                 Consumer Health                  Consumer Health             Consumer Health            Consumer Health           Consumer Health            Consumer Health           Consumer Health            Consumer Health            Consumer Health            Consumer Health           Consumer Health            Consumer Health
            separation tax                     separation tax              separation tax                separation tax               separation tax                separation tax               separation tax                separation tax                  separation tax                   separation tax                  separation tax                   separation tax              separation tax             separation tax            separation tax             separation tax            separation tax             separation tax             separation tax             separation tax            separation tax             separation tax
             related costs                      related costs               related costs                 related costs                related costs                 related costs                related costs                 related costs                   related costs                    related costs                   related costs                    related costs               related costs              related costs             related costs              related costs             related costs              related costs              related costs              related costs             related costs              related costs
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  -------------------- ------------------------------
             Twelve Months                      Twelve Months                In-process                    In-process                   In-process                    In-process                   In-process                    In-process             Acquisition, integration and     Acquisition, integration and    Acquisition, integration and     Acquisition, integration and       (Loss)/gain on             (Loss)/gain on           COVID-19 Vaccine           COVID-19 Vaccine          COVID-19 Vaccine           COVID-19 Vaccine            Consumer Health            Consumer Health           Tax legislation
                                                                      research and development      research and development     research and development      research and development     research and development      research and development         divestiture related (1)          divestiture related (1)         divestiture related (1)          divestiture related (1)           securities                 securities               Related Costs              Related Costs             Related Costs              Related Costs            separation costs           separation costs            and other tax
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      related
                                                                      ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ---------------------------------  ---------------------------- ----------------------------------  ---------------------------- ----------------------------------  -------------------- ------------------------------  -------------------- ------------------------------  -------------------- -------------------------------  -------------------- ------------------------------  --------------------
              Jan 2, 2022                        Jan 2, 2022              Intangible asset              Intangible asset            Litigation related            Litigation related              Restructuring       Restructuring                   Restructuring                  Medical Device    Medical Device           Medical Device                   Medical Device                   Other           Other           Other                Other           Other                      Other                   Jan 2, 2022                Jan 2, 2022
                 GAAP                               GAAP                    amortization                  amortization                                                                               related             related                         related                       Regulation        Regulation               Regulation                       Regulation                                                                                                                                              Non-GAAP                   Non-GAAP
------------------------------------- ------------------------------  ------------------------ --------------------------------  ------------------------ --------------------------------  ------------------------ ------------- ------------------------------------------------  -------------- -------------------- ---------------------------- ----------------------------------  -------------------- ---------- -------------------- -------------------- ---------- ----------------------------------------  ----------- ----------------------------------------
Cost of products sold                                    $     29,855                   (4,661       (4,661 )                                         (86                               (86                      (86                                (86                          (86            (86 )                                             (85                                 (85                  (85                             (85                  (85        (85 )                                  25,023                           25,023               25,023                          25,023               25,023                          25,023               25,023                          25,023               25,023                          25,023               25,023     25,023  
Selling, marketing and admin expenses       24,659                      (24                               (24                      (24                               (24                      (24                                (24                          (24                                 (24                          (24                                 (24                  (24                             (24                  (24        (24 )                                  24,635                           24,635               24,635                          24,635               24,635                          24,635               24,635                          24,635               24,635                          24,635               24,635     24,635  
Research and development expense            14,714                        -                                 -                        -                                 -                        -                                  -                            -                                   -                            -              -                   (125                            (125                 (125       (125 )                                  14,589                           14,589               14,589                          14,589               14,589                          14,589               14,589                          14,589               14,589                          14,589               14,589     14,589  
Other (Income) / Expense                       489                      (36          (36 )                                      (2,328       (2,328 )                                        (135                               (135                         (135           (135 )                                             478            478                    533        533                      -                               -                    -           -                    (67        (67 )                                       -          -                      -                               -                    -          -                 (1,066     (1,066 )
In-process research and development            900                     (900                              (900                     (900                              (900                     (900          (900 )                                               -                                   -                            -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Restructuring                                  252                     (252                              (252                     (252                              (252                     (252                               (252                         (252           (252 )                                               -                                   -                    -                               -                    -                               -                    -                                -                    -                               -                    -                               -                    -                               -                    -                               -                    -          -  
Provision for taxes on income                1,898                      667          667                        481          481                        202           202                             86             86                            (98            (98 )                                    (116       (116 )                                      44         44                      -           -                     15         15                      -          -                  1,090      1,090                      -          -                  4,269      4,269  
Net Earnings                                20,878                    4,030        4,030                      1,847        1,847                        698           698                            387            387                           (380           (380 )                                    (417       (417 )                                     190        190                      -           -                     52         52                      -          -                 (1,090     (1,090 )                                       -          -                 26,195     26,195  
                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                   

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005275/en/

SOURCE: Johnson & Johnson

Press Contacts:

Tesia Williams
media-relations@its.jnj.com

Investor Contacts:

Jessica Moore
RA-JJCUS-InvestorRel@ITS.JNJ.com
comtex tracking

COMTEX_423200286/1006/2023-01-24T06:25:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.